We are developing epigenetic therapies to modulate undruggable immune pathways. Our lead program uses mRNA-delivered epigenetic repressors to silence MYD88, a central driver of hyperinflammation previously considered beyond reach. This approach enables the first targeted treatment for hemophagocytic lymphohistiocytosis (HLH), a fatal orphan disease, while establishing a platform to tackle chronic inflammation, longevity, and age-related immune dysfunction. Our mission is to transform immune control into a precise, durable, and programmable therapy

Contact us: amir@genexgen.com